Atherectomy + DCB Demonstrated Superior Freedom from TLR Rate

The Value of Vessel Pre

Studies suggest that heavily calcified lesions may impact drug delivery. Calcium may act as a mechanical barrier and limit drug uptake, while debulking may aid drug uptake by removing calcium.

“The real challenge in treating the FP artery is in addressing complex disease such as long lesions, total occlusions, and calcified vessels. In lesions such as these, we employ a strategy of vessel prep with atherectomy first, prior to utilizing DCB.” – Dr. Nicolas Shammas, The Emerging Role of Atherectomy in the Era of Drug-Elution.

Hear More about Atherectomy and DCB from Dr. Shammas

JET-SCE Study Details

Shammas, N (2017). Long Term Outcomes with Jetstream Atherectomy System with or without Drug Coated Balloons in Treating Femoropopliteal Arteries: A Single Center Experience (JET-SCE). JET-SCE results presented as a poster at Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions, New Orleans, LA.

The JET-SCE observed the long-term outcomes in treating femoropopliteal arteries with drug coated balloons versus plain old balloon angioplasty post Jetstream™ Atherectomy. The TLR rate was significantly reduced with atherectomy and adjunctive DCB compared to atherectomy with adjunctive PTA at 18-months.

At 12-months results demonstrated 95.2% freedom from TLR with Jetstream + DCB

Patient Characteristics

  • 81 patients
  • 49.4% male
  • 68.3 average age
  • 53.1 % diabetic 

Lesion Characteristics

  • 25.9% CTOs
  • 14.9 cm average lesion length in PTA cohort
  • 12.0 cm average lesion length in DCB cohort
The JET-SCE included patients with de novo or restenotic femoropopliteal lesions whose symptoms were classified as Rutherford Category I-V

Jetstream Device and Procedural Success

  • 87% Device Success (<50% stenosis post Jetstream alone)
  • 94% Procedural Success (<30% residual final treatment)

Minimal Luminal Diameter

  • Baseline: 1.5 mm ± 1.4 mm
  • Post Jetstream: 3.1 mm ± 1.2 mm
  • Post Final Treatment: 4.2 mm ± 0.9 mm

Patient Procedure Details and Outcomes

  • 12-months: Jetstream + DCB 95.2% freedom from TLR
  • 12-months: Jetstream + PTA 69.8% freedom from TLR
  • 18-months: Jetstream + DCB 91.1% freedom from TLR
  • 18-months: Jetstream + PTA 63.7% freedom from TLR
  • 28 patients received adjunctive DCB
  • 53 patients received adjunctive PTA

View the JET-SCE manuscript published in Cardiovascular Revascularization Medicine

In a recent real-world registry, Jetstream demonstrated high freedom from TLR rate and strong safety profile in the
treatment of calcified long femoropopliteal lesions
View JET Registry Data


CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete “Directions for Use” for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator’s Instructions.


The JETSTREAM System is intended for use in atherectomy of the peripheral vasculature and to break apart and remove thrombus from upper and lower extremity peripheral arteries. It is not intended for use in coronary, carotid, iliac or renal vasculature.


The PVCN100 Console is designed for use only with the JETSTREAM Catheter and Control Pod. See the current revision of the applicable Catheter and Control Pod Directions for Use for further information.


None known.


  • Use room temperature infusate only. Use of heated infusate may lead to wrinkling, ballooning and/or bursting of the outer catheter sheath, which could lead to injury to the patient
  • Operating the Catheter over a kinked guidewire may cause vessel damage or guidewire fracture.
  • During treatment, do not allow the Catheter tip within 10.0 cm of spring tip portion of the guidewire. Interaction between the Catheter Tip and this portion of the guidewire may cause damage to or detachment of the guidewire tip or complicate guidewire management.
  • The guidewire must be in place prior to operating the Catheter in the patient. Absence of the guidewire may lead to inability to steer the Catheter and cause potential vessel damage.
  • If the guidewire is accidentally retracted into the device during placement or treatment, stop use, and remove the Catheter and the guidewire from the patient. Verify that the guidewire is not damaged before re-inserting the guidewire. If damage is noticed, replace the guidewire.
  • Check the infusate bag frequently and replace when needed. Do not run the JETSTREAM System without infusate as this may cause device failure.
  • Hold the guidewire firmly during Catheter retraction process. Failure to do so may result in guidewire rotation within the vessel, which could cause patient injury.
  • Do not manipulate the Catheter against resistance unless the cause for that resistance has been determined.
  • Prior to use of the JETSTREAM System, confirm the minimum vessel diameter proximal to the lesion per the following table:


Minimum Vessel Diameter Proximal to Lesion
- Model 1.6 (2.5 mm)
- Model 1.85 (2.75mm)

Minimum Vessel Diameter, Blades Down
- Model 2.1/3.0 (3.0mm)
- Model 2.4/3.4 (3.5mm)

Minimum Vessel Diameter, Blades Up
- Model 2.1/3.0 (4.0mm)
- Model 2.4/3.4 (4.5mm)


  • Do not bend or kink the Catheter during setup or during the procedure. This may damage the device and lead to device failure.
  • Do not inject contrast while the device is activated.
  • Use only listed compatible guidewires and introducers with the JETSTREAM System. The use of any supplies not listed as compatible may damage or compromise the performance of the JETSTREAM System.


  • WARNING: To avoid the risk of electric shock, this equipment must only be connected to a supply mains with protective earth.
  • Do not open either pump door during operation of the System. Doing so could result in loss of aspiration and/or infusion and will halt device activation.
  • Ensure the PVCN100 Console display is visible during the entire procedure.
  • Observe normal safety practices associated with electrical/electronic medical equipment.
  • Avoid excessive coiling or bending of the power cables during storage.
  • Store the PVCN100 Console using appropriate care to prevent accidental damage.
  • Do not place objects on the PV Console.
  • Do not immerse the PV Console in liquids.

ADVERSE EVENTS                                                                                                                                               

Potential adverse events associated with use of this device and other interventional catheters include, but are not limited to the following (alphabetical order):

Abrupt or sub-acute closure


Bleeding complications, access site

Bleeding complications, non-access site



Distal emboli


Infection or fever

Minor burn


Restenosis of the treated segment

Vascular complications which may require surgical repair




More from PV Podium


The Emerging Role of Atherectomy in the Era of Drug-Elution

Dr. Nicolas Shammas discusses femoropopliteal (FP) arterial disease and the potential impact of debulking prior to utilizing drug-coated balloons.


Data Demonstrated High Freedom from TLR and Strong Safety Profile

View results from the JET Registry, including lesion characteristics, efficacy and outcomes, and subgroup results.

Stay Connected

Get the latest peripheral vascular resources sent directly to your inbox.